458 related articles for article (PubMed ID: 22340590)
1. An animal model of MYC-driven medulloblastoma.
Pei Y; Moore CE; Wang J; Tewari AK; Eroshkin A; Cho YJ; Witt H; Korshunov A; Read TA; Sun JL; Schmitt EM; Miller CR; Buckley AF; McLendon RE; Westbrook TF; Northcott PA; Taylor MD; Pfister SM; Febbo PG; Wechsler-Reya RJ
Cancer Cell; 2012 Feb; 21(2):155-67. PubMed ID: 22340590
[TBL] [Abstract][Full Text] [Related]
2. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
3.
Tao R; Murad N; Xu Z; Zhang P; Okonechnikov K; Kool M; Rivero-Hinojosa S; Lazarski C; Zheng P; Liu Y; Eberhart CG; Rood BR; Packer R; Pei Y
Cancer Res; 2019 Apr; 79(8):1967-1980. PubMed ID: 30862721
[TBL] [Abstract][Full Text] [Related]
4. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma.
Maynard RE; Poore B; Hanaford AR; Pham K; James M; Alt J; Park Y; Slusher BS; Tamayo P; Mesirov J; Archer TC; Pomeroy SL; Eberhart CG; Raabe EH
Cancer Lett; 2021 Apr; 504():137-145. PubMed ID: 33571541
[TBL] [Abstract][Full Text] [Related]
5. Molecular and in vivo characterization of cancer-propagating cells derived from MYCN-dependent medulloblastoma.
Ahmad Z; Jasnos L; Gil V; Howell L; Hallsworth A; Petrie K; Sawado T; Chesler L
PLoS One; 2015; 10(3):e0119834. PubMed ID: 25785590
[TBL] [Abstract][Full Text] [Related]
6. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
7. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action and therapeutic efficacy of Aurora kinase B inhibition in MYC overexpressing medulloblastoma.
Diaz RJ; Golbourn B; Faria C; Picard D; Shih D; Raynaud D; Leadly M; MacKenzie D; Bryant M; Bebenek M; Smith CA; Taylor MD; Huang A; Rutka JT
Oncotarget; 2015 Feb; 6(5):3359-74. PubMed ID: 25739120
[TBL] [Abstract][Full Text] [Related]
9. A mouse model of the most aggressive subgroup of human medulloblastoma.
Kawauchi D; Robinson G; Uziel T; Gibson P; Rehg J; Gao C; Finkelstein D; Qu C; Pounds S; Ellison DW; Gilbertson RJ; Roussel MF
Cancer Cell; 2012 Feb; 21(2):168-80. PubMed ID: 22340591
[TBL] [Abstract][Full Text] [Related]
10. Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells.
Kawauchi D; Ogg RJ; Liu L; Shih DJH; Finkelstein D; Murphy BL; Rehg JE; Korshunov A; Calabrese C; Zindy F; Phoenix T; Kawaguchi Y; Gronych J; Gilbertson RJ; Lichter P; Gajjar A; Kool M; Northcott PA; Pfister SM; Roussel MF
Oncogene; 2017 Sep; 36(37):5231-5242. PubMed ID: 28504719
[TBL] [Abstract][Full Text] [Related]
11. Sequential activation of Snail1 and N-Myc modulates sonic hedgehog-induced transformation of neural cells.
Colvin Wanshura LE; Galvin KE; Ye H; Fernandez-Zapico ME; Wetmore C
Cancer Res; 2011 Aug; 71(15):5336-45. PubMed ID: 21646478
[TBL] [Abstract][Full Text] [Related]
12. N-myc can substitute for insulin-like growth factor signaling in a mouse model of sonic hedgehog-induced medulloblastoma.
Browd SR; Kenney AM; Gottfried ON; Yoon JW; Walterhouse D; Pedone CA; Fults DW
Cancer Res; 2006 Mar; 66(5):2666-72. PubMed ID: 16510586
[TBL] [Abstract][Full Text] [Related]
13. Distinct neural stem cell populations give rise to disparate brain tumors in response to N-MYC.
Swartling FJ; Savov V; Persson AI; Chen J; Hackett CS; Northcott PA; Grimmer MR; Lau J; Chesler L; Perry A; Phillips JJ; Taylor MD; Weiss WA
Cancer Cell; 2012 May; 21(5):601-613. PubMed ID: 22624711
[TBL] [Abstract][Full Text] [Related]
14. Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression.
Thomas WD; Chen J; Gao YR; Cheung B; Koach J; Sekyere E; Norris MD; Haber M; Ellis T; Wainwright B; Marshall GM
Oncogene; 2009 Apr; 28(13):1605-15. PubMed ID: 19234491
[TBL] [Abstract][Full Text] [Related]
15. Somatic cell transfer of c-Myc and Bcl-2 induces large-cell anaplastic medulloblastomas in mice.
Jenkins NC; Rao G; Eberhart CG; Pedone CA; Dubuc AM; Fults DW
J Neurooncol; 2016 Feb; 126(3):415-24. PubMed ID: 26518543
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells.
von Bueren AO; Shalaby T; Rajtarova J; Stearns D; Eberhart CG; Helson L; Arcaro A; Grotzer MA
BMC Cancer; 2007 Jan; 7():19. PubMed ID: 17254356
[TBL] [Abstract][Full Text] [Related]
17. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.
Pei Y; Liu KW; Wang J; Garancher A; Tao R; Esparza LA; Maier DL; Udaka YT; Murad N; Morrissy S; Seker-Cin H; Brabetz S; Qi L; Kogiso M; Schubert S; Olson JM; Cho YJ; Li XN; Crawford JR; Levy ML; Kool M; Pfister SM; Taylor MD; Wechsler-Reya RJ
Cancer Cell; 2016 Mar; 29(3):311-323. PubMed ID: 26977882
[TBL] [Abstract][Full Text] [Related]
18. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Buonamici S; Williams J; Morrissey M; Wang A; Guo R; Vattay A; Hsiao K; Yuan J; Green J; Ospina B; Yu Q; Ostrom L; Fordjour P; Anderson DL; Monahan JE; Kelleher JF; Peukert S; Pan S; Wu X; Maira SM; García-Echeverría C; Briggs KJ; Watkins DN; Yao YM; Lengauer C; Warmuth M; Sellers WR; Dorsch M
Sci Transl Med; 2010 Sep; 2(51):51ra70. PubMed ID: 20881279
[TBL] [Abstract][Full Text] [Related]
19. Combined MYC and P53 defects emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable disease.
Hill RM; Kuijper S; Lindsey JC; Petrie K; Schwalbe EC; Barker K; Boult JK; Williamson D; Ahmad Z; Hallsworth A; Ryan SL; Poon E; Robinson SP; Ruddle R; Raynaud FI; Howell L; Kwok C; Joshi A; Nicholson SL; Crosier S; Ellison DW; Wharton SB; Robson K; Michalski A; Hargrave D; Jacques TS; Pizer B; Bailey S; Swartling FJ; Weiss WA; Chesler L; Clifford SC
Cancer Cell; 2015 Jan; 27(1):72-84. PubMed ID: 25533335
[TBL] [Abstract][Full Text] [Related]
20. Modeling medulloblastoma in vivo and with human cerebellar organoids.
Ballabio C; Anderle M; Gianesello M; Lago C; Miele E; Cardano M; Aiello G; Piazza S; Caron D; Gianno F; Ciolfi A; Pedace L; Mastronuzzi A; Tartaglia M; Locatelli F; Ferretti E; Giangaspero F; Tiberi L
Nat Commun; 2020 Jan; 11(1):583. PubMed ID: 31996670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
